Special Issue

Drug Resistant Tuberculosis

Message from the Guest Editors

Multidrug-resistant tuberculosis (MDR-TB) is a threat to tuberculosis (TB) control. The disease is more aggressive, the lung damage is worse, the duration of therapy is much longer, and the adherence to treatment is low. Nowadays, advances in diagnosis techiniques allows for faster dectetion of Mycobacterium tuberculosis and rifampicin resistance trough genotyping tests. The traditional regimen to treat MDR-TB is a 18–24 months long regimen, and the expected cure rates are low (WHO = 59%). One of the greatest challenges to TB treatment outcome, especially in resistant TB cases, is loss to follow-up-due to the risk of acquiring or accumulating resistances and due to transmission cycle maintenace. Therefore, this Special Issue, "Drug-Resistant Tuberculosis", invites submissions of studies addressing resistant TB treatment outcomes, as well as factors related to unfavorable outcomes that could potentially include clinical characteristics, diagnosis, phamacokinetics of drugs, and outcomes, especially loss to follow-up, to quide new potential approaches and for a better understanding of the challenges managing resistant TB cases.

Guest Editors

Dr. Valeria Rolla

Dr. Felipe Ridolfi

Dr. Pruthu Thekkur

Dr. Divya Nair

Deadline for manuscript submissions

closed (28 February 2023)



Tropical Medicine and Infectious Disease

an Open Access Journal by MDPI

Impact Factor 2.6
CiteScore 4.7
Indexed in PubMed



mdpi.com/si/120400

Tropical Medicine and Infectious Disease Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 tropicalmed@mdpi.com

mdpi.com/journal/ tropicalmed





Tropical Medicine and Infectious Disease

an Open Access Journal by MDPI

Impact Factor 2.6 CiteScore 4.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. John Frean

Pathologist, Parasitology Reference Lab, Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases, University of the Witwatersrand, Johannesburg 2192, South Africa

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Informit, and other databases.

Journal Rank:

JCR - Q1 (Tropical Medicine) / CiteScore - Q2 (Public Health, Environmental and Occupational Health)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 20.6 days after submission; acceptance to publication is undertaken in 3.1 days (median values for papers published in this journal in the first half of 2025).

